The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
In silico design of clinical trials: A method coming of age
Abstract
OBJECTIVE: To determine the feasibility and potential usefulness of mathematical models in evaluating immunomodulatory strategies in clinical trials of severe sepsis. DESIGN: Mathematical modeling of immunomodulation in simulated patients. SETTING: Computer laboratory. MEASUREMENTS AND MAIN RESULTS: We introduce and evaluate the concept of conducting a randomized clinical trial in silico based on simulated patients generated from a mechanistic mathematical model of bacterial infection, the acute inflammatory response, global tissue dysfunction, and a therapeutic intervention. Trial populations are constructed to reflect heterogeneity in bacterial load and virulence as well as propensity to mount and modulate an inflammatory response. We constructed a cohort of 1,000 trial patients submitted to therapy with one of three different doses of a neutralizing antibody directed against tumor necrosis factor (anti-TNF) for 6, 24, or 48 hrs. We present cytokine profiles over time and expected outcome for each cohort. We identify subgroups with high propensity for being helped or harmed by the proposed intervention and identify early serum markers for each of those subgroups. The mathematical simulation confirms the inability of simple markers to predict outcome of sepsis. The simulation clearly separates cases with favorable and unfavorable outcome on the basis of global tissue dysfunction. Control survival was 62.9% at 1 wk. Depending on dose and duration of treatment, survival ranged from 57.1% to 80.8%. Higher doses of anti-TNF, although effective, also result in considerable harm to patients. A statistical analysis based on a simulated cohort identified markers of favorable or adverse response to anti-TNF treatment. CONCLUSIONS: A mathematical simulation of anti-TNF therapy identified clear windows of opportunity for this intervention as well as populations that can be harmed by anti-TNF therapy. The construction of an in silico clinical trial could provide profound insight into the design of clinical trials of immunomodulatory therapies, ranging from optimal patient selection to individualized dosage and duration of proposed therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone, R. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-8-199610150-00009 · Cited by 718 · cited 1×
“This situation is especially vexing considering that a reasonable therapeutic rationale was supported by animal and early phase human studies for dozens of interventions that failed when evaluated in phase III (10–12).”
BackgroundMultiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems
Seely, A. J. E., & Christou, N. V. (2000) · Critical Care Medicine · doi:10.1097/00003246-200007000-00003 · Cited by 287
Cited by
Agent‐based models in translational systems biology
An, G., Mi, Q., Dutta‐Moscato, J., & Vodovotz, Y. (2009) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.45 · Cited by 321
Self-citationIn silico clinical trials: how computer simulation will transform the biomedical industry
Viceconti, M., Henney, A., & Morley-Fletcher, E. (2016) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20161408 · Cited by 289
Iwashyna, T. J., Burke, J. F., Sussman, J. B., Prescott, H. C., Hayward, R. A., & Angus, D. C. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2125cp · Cited by 276
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Roberts, M., Russell, L. B., Paltiel, A. D., Chambers, M., McEwan, P., & Krahn, M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.016 · Cited by 241
Multiscale Modeling in the Clinic: Drug Design and Development
Clancy, C. E., An, G., Cannon, W. R., Liu, Y., May, E. E., Ortoleva, P., Popel, A. S., Sluka, J. P., Su, J., Vicini, P., et al. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1563-0 · Cited by 62
Metadata
- Authors
- Clermont, G., Bartels, J., Kumar, R., Constantine, G., Vodovotz, Y., & Chow, C.
- Venue
- Critical Care Medicine
- Published
- 2004-10
- Volume
- 32
- Issue
- 10
- Pages
- 2061-2070
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2023447635
- Cited by
- 189
- References
- 2
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In silico design of clinical trials: A method coming of age. https://app.cochat.ai/papers/10.1097/01.ccm.0000142394.28791.c3
- The paper
- Clermont, G., Bartels, J., Kumar, R., Constantine, G., Vodovotz, Y., & Chow, C. (2004). In silico design of clinical trials: A method coming of age. Critical Care Medicine. https://doi.org/10.1097/01.ccm.0000142394.28791.c3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.